Biocept Reports First Quarter 2017 Financial Results (May 11th, 2017)
SAN DIEGO (May 11, 2017) - Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the three months ended March 31, 2017, and provides an update on its business progress.
Placement Agency Agreement (March 30th, 2017)
Contract (March 28th, 2017)
COMMON STOCK Biocept NUMBER INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE SHARES SEE REVERSE SIDE FOR CERTAIN DEFINITIONS CUSIP 09072V 20 4 THIS CERTIFIES THAT is the owner of FULLY PAID AND NON-ASSESSABLE COMMON SHARES, $0.0001 PAR VALUE, OF BIOCEPT, INC. transferable on the books of the Corporation by the holder hereof in person or by Attorney upon surrender of this certificate properly endorsed. This certificate is not valid until countersigned and registered by the Transfer Agent and Registrar. IN WITNESS WHEREOF, the said Corporation has caused this certificate to be signed by facsimile signatures of its duly authorized officers. Dated: COUNTERSIGNED AND REGISTERED: CONTINENTAL STOCK TRANSFER TRANSFER AGENT AND REGISTRAR BY AUTHORIZED SIGNATURE /s/ Timothy Kennedy (CHIEF FINANCIAL OFFICER, SENIOR VICE PRESIDENT OF OPERATIONS AND CORPORATE SECRETARY) /s/ Michael W. Nall (PRESIDENT AND CHIEF EXECUTIVE OFFICER) Exhibit 4.3
Biocept's CEO Issues Letter to Stockholders (February 9th, 2017)
SAN DIEGO (February 9, 2017) -- Biocept, Inc. (NASDAQ:BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that President and CEO Michael W. Nall has issued the following letter to stockholders:
Second Amendment to Loan and Security Agreement (August 5th, 2016)
THIS SECOND AMENDMENT to Loan and Security Agreement (this "Amendment") is entered into as of June 30, 2016 (the "Amendment Date"), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (in its individual capacity, "Oxford"; and in its capacity as Collateral Agent, "Collateral Agent"), the Lenders listed on Schedule 1.1 to the Loan Agreement (as defined herein) from time to time including Oxford in its capacity as a Lender (each a "Lender" and collectively, the "Lenders") and BIOCEPT, INC., a Delaware corporation with offices located at 5810 Nancy Ridge Drive, San Diego, California 92121 ( "Borrower").
Employment Agreement (July 27th, 2016)
THIS EMPLOYMENT AGREEMENT (this Agreement) is entered into by and between Biocept, Inc., a Delaware corporation (the Company), and Timothy Kennedy (Executive), and shall be effective as of July 25, 2016 (the Effective Date).
Strictly Confidential (April 29th, 2016)
This letter agreement (this "Agreement") constitutes the agreement between Biocept, Inc. (the "Company") and H.C. Wainwright & Co., LLC ("Wainwright") that Wainwright shall serve as the exclusive placement agent in an offering (the "Offering") of securities of the Company ("Securities") during the Term (as defined below) of this Agreement. The terms of the Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright's assistance in the Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwright in connection with the transaction. T